Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Relapsed/Refractory B Cell Malignancies”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT01520922
What this trial is testing

Ofatumumab Plus Bendamustine in Frontline and Relapsed Chronic Lymphocytic Leukaemia (CLL)

Who this might be right for
Chronic Lymphocytic Leukemia (CLL)Leukaemia, Lymphocytic, Chronic
Novartis Pharmaceuticals 99
Early research (Phase 1)Study completedNCT00735930
What this trial is testing

Lenalidomide and Alvocidib in Treating Patients With Relapsed or Refractory B-cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Who this might be right for
AnemiaChronic Lymphocytic LeukemiaProlymphocytic Leukemia+3 more
National Cancer Institute (NCI) 39
Not applicableStudy completedNCT00003538
What this trial is testing

Prevention of Graft-Versus-Host Disease in Patients Undergoing Bone Marrow Transplantation

Who this might be right for
Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Testing effectiveness (Phase 2)UnknownNCT03207178
What this trial is testing

Sequential Infusion of Anti-CD19 and Anti-CD20 CAR-T Cells Against Relapsed and Refractory B-cell Lymphoma

Who this might be right for
Recurrent or Refractory B Cell Malignancy
Shanghai Longyao Biotechnology Inc., Ltd. 20
Testing effectiveness (Phase 2)Ended earlyNCT05117008
What this trial is testing

Maintenance Belantamab Mafodotin (Blenrep®) After B-cell Maturation Antigen-Directed Chimeric Antigen Receptor T-cell Therapy in Patients With Relapsed and/or Refractory Multiple Myeloma

Who this might be right for
Refractory Multiple MyelomaRelapse Multiple Myeloma
Medical College of Wisconsin 1
Early research (Phase 1)Study completedNCT00058396
What this trial is testing

Monoclonal Antibody in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Who this might be right for
LeukemiaLymphoma
Memorial Sloan Kettering Cancer Center
Large-scale testing (Phase 3)Ended earlyNCT00324324
What this trial is testing

Moxifloxacin in Preventing Bacterial Infections in Patients Who Have Undergone Donor Stem Cell Transplant

Who this might be right for
Breast CancerChronic Myeloproliferative DisordersGestational Trophoblastic Tumor+9 more
OHSU Knight Cancer Institute 240
Testing effectiveness (Phase 2)Ended earlyNCT05588440
What this trial is testing

A Clinical Study of ONCT-808 in Subjects With Relapsed or Refractory B-Cell Malignancies

Who this might be right for
Relapsed/Refractory Aggressive B-Cell Malignancies
Oncternal Therapeutics, Inc 9
Testing effectiveness (Phase 2)WithdrawnNCT03999658
What this trial is testing

STI-3031 (an Anti-PD-L1 Antibody) in Patients With Selected Relapsed/Refractory Malignancies

Who this might be right for
Peripheral T Cell LymphomaDiffuse Large B Cell LymphomaBiliary Tract Cancer+1 more
Sorrento Therapeutics, Inc.
Testing effectiveness (Phase 2)Study completedNCT02600897
What this trial is testing

Obinutuzumab, Polatuzumab Vedotin, and Lenalidomide in Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab in Combination With Polatuzumab Vedotin and Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Who this might be right for
Relapsed or Refractory Follicular Lymphoma, Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Hoffmann-La Roche 114
Testing effectiveness (Phase 2)Study completedNCT03196830
What this trial is testing

CAR-T for R/R B-NHL

Who this might be right for
Relapsed Non Hodgkin LymphomaRefractory Non-Hodgkin LymphomaCAR - T CD19/CD20/CD22/CD30
The First Affiliated Hospital of Soochow University 168
Testing effectiveness (Phase 2)Looking for participantsNCT04150497
What this trial is testing

Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)

Who this might be right for
B-cell Acute Lymphoblastic Leukemia
Cellectis S.A. 52
Early research (Phase 1)Looking for participantsNCT06326008
What this trial is testing

Safety, Tolerability, and Pharmacokinetics of Donor-derived CD19 CAR Therapy Bridged Allo-HSCT and Sequential Donor-derived CD22 CAR Therapy for r/r B-ALL: a Clinical Trial

Who this might be right for
B-cell Acute Lymphoblastic LeukemiaAcute Lymphoblastic Leukemia, in Relapse
Beijing GoBroad Hospital 48
Early research (Phase 1)Study completedNCT04317885
What this trial is testing

A Study Evaluating Safety and Efficacy of C-CAR039 Treatment in NHL Subjects

Who this might be right for
Non-Hodgkin's B-cell Lymphoma
Shanghai Tongji Hospital, Tongji University School of Medicine 25
Early research (Phase 1)Looking for participantsNCT05794958
What this trial is testing

Evaluate Safety of Axicabtagene Ciloleucel Reinfusion (Axi-Cel-2) in Patients With Relapsed and/or Refractory Second Line High-Risk Non-Hodgkin Lymphoma After Standard of Care Axi-Cel

Who this might be right for
Non-Hodgkin LymphomaLarge B-cell Lymphoma
Stanford University 20
Testing effectiveness (Phase 2)UnknownNCT00385125
What this trial is testing

Treatment of Patients With Relapsed or Primary Refractory Aggressive B- Cell NHL

Who this might be right for
Lymphoma, High-Grade
University of Magdeburg 30
Very early researchLooking for participantsNCT07240974
What this trial is testing

Safety and Efficacy of ZZSW-01 in Relapsed/Refractory B-cell Malignancies

Who this might be right for
Relapsed/Refractory B-cell Malignancies
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology 6
Not applicableApproved For MarketingNCT04300803
What this trial is testing

Expanded Access Program for Tafasitamab (MOR00208) in R/R DLBCL

Who this might be right for
DLBCL
MorphoSys AG
Early research (Phase 1)Ended earlyNCT03778073
What this trial is testing

Study of Cosibelimab in Subjects With Relapsed or Refractory Lymphoma

Who this might be right for
B-cell Non Hodgkin LymphomaRichter's Transformation
TG Therapeutics, Inc. 18
Early research (Phase 1)Looking for participantsNCT06879340
What this trial is testing

Evaluating the Safety and Efficacy of DuoCAR20.19.22-D95 in Adult Patients With Relapsed or Refractory B-cell Malignancies

Who this might be right for
B-Cell Non-Hodgkin LymphomaB-cell Acute Lymphoblastic Leukemia
University of Kansas Medical Center 54
Next Page